BioXcel Therapeutics Corp (BTAI) - Cash Funds per Share

Symbol and logo of brand BioXcel Therapeutics Corp (BTAI)

Cash per share trends demonstrate the liquidity of BioXcel Therapeutics (BTAI), where the latest value is recorded as 0.44. BioXcel Therapeutics (BTAI) is implementing AI for drug repositioning, launching IGALMI for the treatment of psychiatric disorders. The application of neural networks accelerates development, optimizing product costs. Meanwhile, management is restoring its reputation by strengthening internal controls and proving the effectiveness of its commercial strategy in neurology.

BioXcel Therapeutics (BTAI) Cash Funds per Share: for the period 07/04/2022 - 09/19/2026

Comprehensive metric breakdowns and analytics for BioXcel Therapeutics Inc (BTAI)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:BTAI (BioXcel Therapeutics Corp)
Product sample of BioXcel Therapeutics, Inc.

For BioXcel Therapeutics (BTAI), which develops complex supply chains for neurological drugs, this indicator determines the internal financial stability of each share. The metric is calculated by dividing the total volume of liquid assets by the number of outstanding shares. By analyzing the cash per share chart, an investor assesses the actual capital reserve available to cover operating expenses. The current value of 0.44 reflects the company's ability to maintain distribution without the emergency procurement of borrowed funds. An increase in this indicator confirms a reduction in the risks of logistical disruptions.